ATE407207T1 - Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung - Google Patents

Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Info

Publication number: ATE407207T1
Authority: AT; Austria
Prior art keywords: nervous system; peripheral nervous; methods; encodes; dna
Prior art date: 1994-11-02

Application number

AT95939723T

Other languages

English (en)

Inventor

Gail Mandel

Simon Halegoua

Laurence A Borden

Original Assignee

Trophix Pharm Inc

Univ New York State Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-02

Filing date

1995-11-02

Publication date

2008-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE407207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-11-02 Application filed by Trophix Pharm Inc, Univ New York State Res Found filed Critical Trophix Pharm Inc

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE407207T1 publication Critical patent/ATE407207T1/de

Links

108010052164 Sodium Channels Proteins 0.000 title abstract 4
102000018674 Sodium Channels Human genes 0.000 title abstract 4
210000001428 peripheral nervous system Anatomy 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 2
238000010367 cloning Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229940039227 diagnostic agent Drugs 0.000 abstract 1
239000000032 diagnostic agent Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000000302 molecular modelling Methods 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)

AT95939723T 1994-11-02 1995-11-02 Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung ATE407207T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33402994A	1994-11-02	1994-11-02
US48240195A	1995-06-07	1995-06-07

Publications (1)

Publication Number	Publication Date
ATE407207T1 true ATE407207T1 (de)	2008-09-15

Family

ID=26989015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95939723T ATE407207T1 (de)	1994-11-02	1995-11-02	Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Country Status (13)

Country	Link
US (5)	US6110672A (de)
EP (2)	EP1985703A3 (de)
JP (5)	JP2000503521A (de)
AT (1)	ATE407207T1 (de)
AU (1)	AU697465B2 (de)
CA (1)	CA2204355C (de)
DE (1)	DE69535830D1 (de)
DK (1)	DK0789575T3 (de)
ES (1)	ES2314978T3 (de)
MX (1)	MX9703187A (de)
NZ (1)	NZ296748A (de)
PT (1)	PT789575E (de)
WO (1)	WO1996014077A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2204355C (en)	1994-11-02	2001-01-16	Gail Mandel	Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US6184349B1 (en)	1995-10-11	2001-02-06	Syntex (Usa) Inc.	Cloned peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit
US6030810A (en) *	1997-02-26	2000-02-29	Delgado; Stephen Gregory	Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
EP0875570A3 (de) *	1997-05-01	1999-12-22	Smithkline Beecham Plc	Neurodegenerative Polypeptide HHPDZ65
CH693031A5 (de) *	1997-11-20	2003-01-31	Hoffmann La Roche	Nucleinsäure, die einen Nervengewebe-Natriumkanal kodiert.
WO2000058469A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	48 human secreted proteins
US7083777B1 (en) *	1999-04-02	2006-08-01	The Brigham And Women's Hospital, Inc.	Immunomodulating polymers
AU1846501A (en)	1999-11-26	2001-06-04	Bionomics Limited	Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
AU2001273888A1 (en) *	2000-07-05	2002-01-14	Neurosearch A/S	New sodium channel (rnav1.5a) and use thereof
GB0021617D0 (en) *	2000-09-02	2000-10-18	Imp College Innovations Ltd	Diagnosis and treatment of cancer
WO2002024722A2 (en) *	2000-09-19	2002-03-28	Prochon Biotech Ltd.	Crystalline fgf9 dimer and methods of use
DE10054878A1 (de) *	2000-11-06	2002-05-08	Boehringer Ingelheim Int	Natriumkanäle vom Typus der peripheren Nerven
SV2003000753A (es)	2000-12-05	2003-06-16	Brigham & Womens Hospital	Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
EP1468293A1 (de) *	2002-01-17	2004-10-20	EVOTEC Neurosciences GmbH	Diagnose und therapie neurodegenerativer erkrankungen mittels des spannungsabhängingen ionenkanals scn2a
US7659082B2 (en)	2002-02-19	2010-02-09	Xenon Pharmaceuticals Inc.	Methods for identifying analgesic agents
US9278088B2 (en)	2002-02-19	2016-03-08	Xenon Pharmaceuticals Inc.	Methods for identifying analgesic agents
AU2003219933A1 (en)	2002-02-25	2003-09-09	Vanderbilt University	Expression system for human brain-specific voltage-gated sodium channel, type 1
WO2004050857A2 (en) *	2002-12-04	2004-06-17	Euro-Celtique S.A.	Splice variant of human sodium iii channel (hnaiii18)
AU2004227852B2 (en)	2003-03-31	2010-01-14	The Brigham And Women's Hospital, Inc.	Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2005069969A2 (en) *	2004-01-21	2005-08-04	University Of Utah Research Foundation	Mutant sodium channel nav1.7 and methods related thereto
US20050201995A1 (en) *	2004-02-05	2005-09-15	Board Of Regents, The University Of Texas System	Methods and compositions related to neuronal differentiation
US7485468B2 (en)	2004-10-15	2009-02-03	Galapagos Bv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2007092451A2 (en)	2006-02-06	2007-08-16	The Brigham And Women's Hospital, Inc.	Zwitterionic polysaccharides for promotion of immune system maturation and health
CN101678127A (zh) *	2007-06-14	2010-03-24	哈默史密斯网上成像有限公司	神经活性的测定
US20120283116A1 (en)	2009-09-11	2012-11-08	Leppert Mark F	Mutant Sodium Channel Nav1.7 and Methods Related Thereto
US9539281B2 (en)	2011-07-12	2017-01-10	The Brigham And Women's Hospital, Inc.	Lipid-containing PSA compositions, methods of isolation and methods of use thereof
CN108135167B (zh)	2015-08-19	2021-07-09	哈佛学院院长及董事	脂化psa组合物和方法
WO2018014012A1 (en)	2016-07-15	2018-01-18	President And Fellows Of Harvard College	Glycolipid compositions and methods of use
EP4695399A2 (de) *	2023-04-13	2026-02-18	The Medical College of Wisconsin, Inc.	Spannungsgesteuerte natriumkanalspezifische peptidaptamere und verwendungen davon

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL137318C (de)	1964-06-09
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4500530A (en) *	1980-11-26	1985-02-19	Boucher John H	Method of treating horses to inhibit or reduce increases in crenated red blood cells during exercise
US4405712A (en)	1981-07-01	1983-09-20	The United States Of America As Represented By The Department Of Health And Human Services	LTR-Vectors
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766067A (en)	1985-05-31	1988-08-23	President And Fellows Of Harvard College	Gene amplification
DE3689123T2 (de)	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US5322770A (en)	1989-12-22	1994-06-21	Hoffman-Laroche Inc.	Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4795699A (en)	1987-01-14	1989-01-03	President And Fellows Of Harvard College	T7 DNA polymerase
US4921794A (en)	1987-01-14	1990-05-01	President And Fellows Of Harvard College	T7 DNA polymerase
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US5142033A (en)	1988-09-23	1992-08-25	Hoffmann-La Roche Inc.	Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en)	1988-09-23	1991-11-19	Cetus Corporation	Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en)	1988-09-23	1992-02-25	Cetus Corporation	Structure-independent dna amplification by the polymerase chain reaction
US5082670A (en)	1988-12-15	1992-01-21	The Regents Of The University Of California	Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4994370A (en)	1989-01-03	1991-02-19	The United States Of America As Represented By The Department Of Health And Human Services	DNA amplification technique
CA2045129A1 (en)	1989-02-01	1990-08-02	Alfred I. Geller	Herpes simplex virus type i expression vector
US5380836A (en) *	1989-02-13	1995-01-10	Arch Development Corporation	Nucleic acid encoding sodium channel protein
WO1990009391A1 (en) *	1989-02-13	1990-08-23	Arch Development Corporation	Nucleic acid encoding sodium channel protein
EP0445749B1 (de) *	1990-03-08	1996-07-10	Fujisawa Pharmaceutical Co., Ltd.	N-Monosubstituierte Cyclopentenylamine, ein Verfahren zu ihrer Herstellung, und ihre Verwendung als Medikament
IE911869A1 (en)	1990-06-01	1991-12-04	Regeneron Pharma	A family of map2 protein kinases
JP2709311B2 (ja)	1990-09-28	1998-02-04	エフ．ホフマン−ラロシュアクチェンゲゼルシャフト	熱安定性ｄｎａポリメラーゼの５→３′のエキソヌクレアーゼ突然変異
WO1992006693A1 (en)	1990-10-22	1992-04-30	Fox Chase Cancer Center	Dna construct for providing rna therapy
AU2468992A (en)	1991-08-16	1993-03-16	General Hospital Corporation, The	Method of gene delivery to post-mitotic cells
US5356777A (en) *	1992-10-01	1994-10-18	University Of Pittsburgh	Methods of detecting periodic paralysis in horses
US5338671A (en)	1992-10-07	1994-08-16	Eastman Kodak Company	DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5340728A (en)	1992-12-09	1994-08-23	E. I. Du Pont De Nemours And Company	Method for amplification of targeted segments of nucleic acid using nested polymerase chain reaction
WO1994014978A1 (de)	1992-12-18	1994-07-07	Strack Hans B	Verbesserte ausbeuten von pcr-produkten in gegenwart von dna-einzelstrang bindendem protein und dessen präparation aus thermus flavus
CA2204355C (en)	1994-11-02	2001-01-16	Gail Mandel	Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof

1995
- 1995-11-02 CA CA002204355A patent/CA2204355C/en not_active Expired - Fee Related
- 1995-11-02 ES ES95939723T patent/ES2314978T3/es not_active Expired - Lifetime
- 1995-11-02 EP EP08102871A patent/EP1985703A3/de not_active Withdrawn
- 1995-11-02 US US08/836,325 patent/US6110672A/en not_active Expired - Lifetime
- 1995-11-02 DK DK95939723T patent/DK0789575T3/da active
- 1995-11-02 AT AT95939723T patent/ATE407207T1/de active
- 1995-11-02 PT PT95939723T patent/PT789575E/pt unknown
- 1995-11-02 NZ NZ296748A patent/NZ296748A/xx not_active IP Right Cessation
- 1995-11-02 WO PCT/US1995/014251 patent/WO1996014077A1/en not_active Ceased
- 1995-11-02 DE DE69535830T patent/DE69535830D1/de not_active Expired - Lifetime
- 1995-11-02 MX MX9703187A patent/MX9703187A/es unknown
- 1995-11-02 JP JP8515424A patent/JP2000503521A/ja not_active Withdrawn
- 1995-11-02 EP EP95939723A patent/EP0789575B8/de not_active Revoked
- 1995-11-02 AU AU41434/96A patent/AU697465B2/en not_active Ceased
1999
- 1999-12-09 US US09/457,571 patent/US6703486B2/en not_active Expired - Fee Related
2002
- 2002-05-17 JP JP2002143880A patent/JP2003047484A/ja active Pending
2004
- 2004-01-29 US US10/768,798 patent/US20040229792A1/en not_active Abandoned
2006
- 2006-12-29 JP JP2006356815A patent/JP2007169286A/ja active Pending
2007
- 2007-06-06 US US11/810,882 patent/US20090029415A1/en not_active Abandoned
- 2007-06-06 US US11/810,919 patent/US8012748B2/en not_active Expired - Fee Related
2008
- 2008-10-31 JP JP2008282154A patent/JP2009055921A/ja active Pending
- 2008-10-31 JP JP2008282171A patent/JP2009118844A/ja active Pending

Also Published As

Publication number	Publication date
JP2000503521A (ja)	2000-03-28
WO1996014077A1 (en)	1996-05-17
DE69535830D1 (de)	2008-10-16
US6703486B2 (en)	2004-03-09
EP0789575B8 (de)	2009-01-14
NZ296748A (en)	1999-11-29
EP0789575A1 (de)	1997-08-20
JP2003047484A (ja)	2003-02-18
DK0789575T3 (da)	2009-01-12
PT789575E (pt)	2008-12-15
US6110672A (en)	2000-08-29
JP2007169286A (ja)	2007-07-05
AU697465B2 (en)	1998-10-08
US20040229792A1 (en)	2004-11-18
CA2204355A1 (en)	1996-05-17
US20090029415A1 (en)	2009-01-29
US20090203122A1 (en)	2009-08-13
EP1985703A2 (de)	2008-10-29
US8012748B2 (en)	2011-09-06
AU4143496A (en)	1996-05-31
EP1985703A3 (de)	2009-04-08
MX9703187A (es)	1998-02-28
US20030092645A1 (en)	2003-05-15
ES2314978T3 (es)	2009-03-16
CA2204355C (en)	2001-01-16
EP0789575B1 (de)	2008-09-03
JP2009055921A (ja)	2009-03-19
EP0789575A4 (de)	2000-11-08
JP2009118844A (ja)	2009-06-04

Legal Events

Date

Code

Title

Description

2009-08-15

UEP

Publication of translation of european patent specification

Ref document number: 0789575

Country of ref document: EP

Publication	Publication Date	Title
DE69535830D1 (de)	2008-10-16	Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
DE69739860D1 (de)	2010-06-02	Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen
RU95115239A (ru)	1997-03-27	Аналог эритропоэтина
DK0559884T4 (da)	2004-08-02	Rekombinante virusvektorer til ekspression i muskelceller
NO934235L (no)	1994-01-20	Anvendelse av nukleinsyreanaloger for diagnostiske og analytiske fremgangsmaater
DE59915205D1 (de)	2010-10-28	Strukturprotein von AAV, seine Herstellung und Verwendung
ES2193144T3 (es)	2003-11-01	Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
AR003961A1 (es)	1998-09-30	Moleculas de acido nucleico
BR9812791A (pt)	2000-10-17	Sequências de ácido nucléico associadas à virulência e seu uso
EP0232523A3 (en)	1988-12-07	Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
MXPA00006306A (es)	2004-09-10	Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.
MXPA94001321A (es)	2003-10-29	Funcion y actividad de la proteina viral r.
ES2170747T3 (es)	2002-08-16	Analogos superiores de trombomodulina para uso farmaceutico.
DK0804467T3 (da)	2003-04-22	Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen
DE69632457D1 (de)	2004-06-17	Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung
ATE26710T1 (de)	1987-05-15	Substituierte tert.-butanol-derivate, verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel.
AR013801A1 (es)	2001-01-10	Nuevas moleculas de acido nucleico aislada, una proteina de epoxido hidrolasa de artropodo hematofago aislada, una formulacion de proteinas deepoxido hidrolasa de pulga, una composicion terapeutica que reduce la infestacion de ectoparasitos hematofagos; uso de dicha composicion para la
FR2766487B1 (fr)	1999-08-27	Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
DE69929683D1 (de)	2006-04-13	Antisense modulierung von lfa-3
PT914417E (pt)	2004-12-31	Dnase ii humana
AU2347501A (en)	2001-05-14	Trp-protein-related mtr1 protein and dna sequence coding therefor
DE60119385D1 (de)	2006-06-08	Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen
Bard et al.	1992	Sequence and genomic locus of a Leishmania protein homologous to rat ribosomal protein S8
TW372973B (en)	1999-11-01	Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
ATE55411T1 (de)	1990-08-15	Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.